^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABN501

    i
    Other names: ABN501, ABN 501
    Associations

    News

    Trials
    Company:
    Abion
    Drug class:
    CLDN3 inhibitor
    Associations

    News

    Trials
    almost3years
    ABN501, a novel anti-claudin-3 antibody, shows potent anti-cancer activity in vitro and in vivo (AACR 2023)
    In summary, we suggest that ABN501 can be used as promising tissue-agnostic drug candidates as therapeutics for various types of claudin-3-positive cancers. ABN501 is currently developed with various antibody engineering platforms.
    Preclinical
    |
    FCGR3A (Fc Fragment Of IgG Receptor IIIa) • CLDN3 (Claudin 3)
    |
    ABN501